You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,511,055

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,511,055

Title:	Angiotensin in treating brain conditions
Abstract:	The present invention provides, among other things, methods and compositions for treating brain conditions. In some embodiments, the methods include administering to a subject suffering from or susceptible to a brain condition an angiotensin (1-7) peptide via either an intravenous or subcutaneous route of administration.
Inventor(s):	Franklin; Richard (Cambridge, MA)
Assignee:	Tarix Pharmaceuticals Ltd. (Cambridge, MA)
Application Number:	13/897,051
Patent Claims:	1. A method of treating stroke comprising administering to a subject suffering from stroke an angiotensin (1-7) peptide comprising the amino acid sequence Asp.sup.1-Arg.sup.2-Val.sup.3-Tyr.sup.4-Ile.sup.5-His.sup.6-Pro.sup.7 (SEQ ID NO: 1) via systemic administration, wherein the systemic administration is not intracerebroventricular administration, and wherein the angiotensin (1-7) peptide is administered without the use of modified stem cells. 2. The method of claim 1, wherein the stroke is either ischemic stroke, hemorrhagic stroke, or a combination thereof. 3. The method of claim 1, wherein the angiotensin (1-7) peptide is administered via continuous infusion. 4. The method of claim 1, wherein the angiotensin (1-7) peptide is administered daily. 5. The method of claim 1, wherein the angiotensin (1-7) peptide is administered twice daily. 6. The method of claim 1, wherein the angiotensin (1-7) peptide is administered twice per month. 7. The method of claim 1, wherein the angiotensin (1-7) peptide is administered once per month. 8. The method of claim 1, wherein the angiotensin (1-7) peptide is administered at an effective dose ranging from about 1-1,500 ug/kg/day. 9. The method of claim 1, wherein the angiotensin (1-7) peptide is administered at an effective dose ranging from about 500-1,500 ug/kg/day. 10. The method of claim 1, wherein the angiotensin (1-7) peptide is administered at an effective dose ranging from about 800-1,200 ug/kg/day. 11. The method of claim 1, wherein the angiotensin (1-7) peptide comprises one or more chemical modifications to increase protease resistance, serum stability and/or bioavailability. 12. The method of claim 11, wherein the one or more chemical modifications comprise pegylation, acetylation, glycosylation, biotinylation, or substitution with D-amino acid or un-natural amino acid. 13. The method of claim 1, wherein the systemic administration is selected from intravenous administration, subcutaneous administration, inhalation, intradermal administration, transdermal administration, transmucosal administration, and/or oral administration. 14. The method of claim 13, wherein the systemic administration is intravenous administration. 15. The method of claim 13, wherein the systemic administration is subcutaneous administration. 16. The method of claim 1, wherein the angiotensin (1-7) peptide is administered as a component of a pharmaceutical composition comprising the angiotensin (1-7) peptide and a pharmaceutically acceptable excipient. 17. The method of claim 1, wherein the angiotensin (1-7) peptide is administered as a part of a combination therapy including at least one additional therapeutic or treatment for stroke. 18. The method of claim 17, wherein the at least one additional therapeutic or treatment for stroke is selected from a thrombolytic compound, an antioxidant, interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, and Teriflunomide, or combinations thereof.

Details for Patent 9,511,055

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	07/23/1993	⤷ Try a Trial	2032-10-02
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996	⤷ Try a Trial	2032-10-02
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003	⤷ Try a Trial	2032-10-02
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012	⤷ Try a Trial	2032-10-02
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	03/07/2002	⤷ Try a Trial	2032-10-02
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	12/17/2004	⤷ Try a Trial	2032-10-02
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	12/21/2012	⤷ Try a Trial	2032-10-02
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.